Reddy’s Gets Six-Month Head Start On Carboprost In US

Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.

Dartboard
Dr Reddy's is eligible for 180-day market exclusivity for the generic carboprost tromethamine vials it has just launched in the US • Source: Shutterstock

Dr Reddy’s Laboratories will benefit from six months of market exclusivity for the first generic rival to Pfizer’s Hemabate carboprost tromethamine single-dose vials that the Indian firm has introduced upon approval in the US.

By securing final approval from the Food and Drug Administration for the 250µg/1ml vials as a competitive generic therapy (CGT),...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin